Central Nervous System Tissue Organogenesis via Precise Growth Factor Tethering

Information

  • Research Project
  • 9238805
  • ApplicationId
    9238805
  • Core Project Number
    R21NS096571
  • Full Project Number
    5R21NS096571-02
  • Serial Number
    096571
  • FOA Number
    PA-12-284
  • Sub Project Id
  • Project Start Date
    7/1/2016 - 7 years ago
  • Project End Date
    6/30/2018 - 5 years ago
  • Program Officer Name
    JAKEMAN, LYN B
  • Budget Start Date
    7/1/2017 - 6 years ago
  • Budget End Date
    6/30/2018 - 5 years ago
  • Fiscal Year
    2017
  • Support Year
    02
  • Suffix
  • Award Notice Date
    6/28/2017 - 6 years ago
Organizations

Central Nervous System Tissue Organogenesis via Precise Growth Factor Tethering

? DESCRIPTION (provided by applicant): Spinal cord injury (SCI) results in permanent loss of sensory input and motor function below the damaged region of the spinal cord. There is currently no available treatment for SCI to recover lost function. One exciting prospective strategy is the administration of stem cells to regenerate and functionally restore damaged spinal cord tissue. However, this approach is fraught with challenges as delivered cells lack the instructive cues necessary for successful integration and outcomes; most clinical work simply transfuses patients with stem cells which proves insufficient for treating SCI. Biomaterial-based strategies offer a solution to this challenge: rather than expecting the stem cells to integrate on their own, we can provide them with a support structure and the necessary instructive cues. We have shown that a naturally-derived hydrogel material, methacrylamide chitosan (MAC), can safely encapsulate adult neural stem cells (aNSCs) and provide a biomimetic matrix necessary for in vivo transplantation. Additionally, we can immobilize important lineage-specifying signaling proteins to this material through a unique application of protein engineering and click chemistry. Recently, we discovered that, when exposed to the subcutaneous environment, aNSCs encapsulated within a MAC-based neural guidance conduit and with a single immobilized neurogenic fusion protein will form developing neural epithelium. This is important, as neural epithelium represents an immature precursor to mature central nervous system (CNS) tissue. Thus, we hypothesize that our engineered conduit could be matured ectopically within the subcutaneous tissue and then transplanted into a damaged spinal cord, where it would develop and integrate with damaged tissue. This new SCI treatment paradigm will be approached through two aims. First, we aim to quantify and substantiate the environment that leads to the formation of nascent neural tubes in constructs implanted in subcutaneous tissue. Second, we aim to improve and implement the subcutaneous- matured construct to treat SCI. As we progress through this project, the information gained will be of use not only to treat SCI but also to help understand the complex behavior of stem cell-biomaterial interactions.

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R21
  • Administering IC
    NS
  • Application Type
    5
  • Direct Cost Amount
    125000
  • Indirect Cost Amount
    65000
  • Total Cost
    190000
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    853
  • Ed Inst. Type
    BIOMED ENGR/COL ENGR/ENGR STA
  • Funding ICs
    NINDS:190000\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    BTSS
  • Study Section Name
    Bioengineering, Technology and Surgical Sciences Study Section
  • Organization Name
    UNIVERSITY OF AKRON
  • Organization Department
    ENGINEERING (ALL TYPES)
  • Organization DUNS
    045207552
  • Organization City
    AKRON
  • Organization State
    OH
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    443250001
  • Organization District
    UNITED STATES